Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Thoracic 1

Conditions

Prostatic Neoplasms 68Prostatic Neoplasms, Castration-Resistant 6Metastatic Castration-resistant Prostate Cancer 6Neoplasms 4Metastatic Castration Resistant Prostate Cancer 4Urogenital Neoplasms 3Prostate Cancer Metastatic 3Neoplasm Metastasis 3Metastatic Castration-Resistant Prostate Cancer 3Genital Neoplasms, Male 3Breast Neoplasms 3Prostatic Diseases 2Neoplasms by Site 2Genital Diseases, Male 2Carcinoma, Non-Small-Cell Lung 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1NSCLC Harboring NRG1 Fusion 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Male Urogenital Diseases 1Hyperaldosteronism 1Colorectal Neoplasms 1Advanced Prostate Cancer 1Advanced Cancer 1Adenocarcinoma 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × Abiraterone Acetate × Clear all
NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

CellCentric Ltd.

Phase 1/2 Completed
220 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT01517802 2022-05-10

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Janssen Research & Development, LLC

Phase 3 Completed
32 enrolled 7 charts
Breast

Breast Neoplasms

NCT01381874 2019-04-11

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Janssen Research & Development, LLC

Phase 2 Completed
297 enrolled 19 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡